Table 2 Clinical evaluations at time of reduction in sural SAP amplitude, stop therapy and after discontinuation of thalidomide treatment
PatientsSural SAPa (%)SymptomsNSSSSSural SAPa* (%)NSS*SS*NSS FUSS FU
1−70None056−80.9056056
2−72None056−72056056
3−100Paresthesias254−100254254
4−100Paresthesias/cramps452−100452252
5−100Numbness256−100256056
6−52None056−73.8056056
7−53None056−48056056
8−52None056−75056056
9−54None056−61056056
10−44Paresthesias/cramps452−44452252
11−40Paresthesias/cramps448−40448248
120None0560056056

  • Sural SAPa: percentage of sural nerve sensory action potential amplitude reduction referred to baseline at time of reduction.

  • NSS: Neurological Symptom Score at time of reduction in sural SAP amplitude (0 = normal; 17 = maximum disability).

  • SS: Sensibility Score at time of reduction in sural SAP amplitude (56 = normal; 0 = maximum disability).

  • Sural SAPa*: percentage of sural nerve sensory action potential amplitude reduction referred to baseline at stop therapy.

  • NSS*: Neurological Symptom Score at stop therapy.

  • SS*: Sensibility Score at stop therapy.

  • NSS FU: Neurological Symptom Score at follow-up post treatment (0 = normal; 17 = maximum disability).

  • SS FU: Sensibility Score at follow-up post-treatment (56 = normal; 0 = maximum disability).